Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1238351.RAfxw3GWNnFVfM9fhovClKpH1xoAqrs3Q3zBz_3q45euI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1238351.RAfxw3GWNnFVfM9fhovClKpH1xoAqrs3Q3zBz_3q45euI130_assertion type Assertion NP1238351.RAfxw3GWNnFVfM9fhovClKpH1xoAqrs3Q3zBz_3q45euI130_head.
- NP1238351.RAfxw3GWNnFVfM9fhovClKpH1xoAqrs3Q3zBz_3q45euI130_assertion description "[Combining valosin-containing protein (VCP) inhibition and suberanilohydroxamic acid (SAHA) treatment additively enhances the folding, trafficking, and function of epilepsy-associated ?-aminobutyric acid, type A (GABAA) receptors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1238351.RAfxw3GWNnFVfM9fhovClKpH1xoAqrs3Q3zBz_3q45euI130_provenance.
- NP1238351.RAfxw3GWNnFVfM9fhovClKpH1xoAqrs3Q3zBz_3q45euI130_assertion evidence source_evidence_literature NP1238351.RAfxw3GWNnFVfM9fhovClKpH1xoAqrs3Q3zBz_3q45euI130_provenance.
- NP1238351.RAfxw3GWNnFVfM9fhovClKpH1xoAqrs3Q3zBz_3q45euI130_assertion SIO_000772 25406314 NP1238351.RAfxw3GWNnFVfM9fhovClKpH1xoAqrs3Q3zBz_3q45euI130_provenance.
- NP1238351.RAfxw3GWNnFVfM9fhovClKpH1xoAqrs3Q3zBz_3q45euI130_assertion wasDerivedFrom befree-2016 NP1238351.RAfxw3GWNnFVfM9fhovClKpH1xoAqrs3Q3zBz_3q45euI130_provenance.
- NP1238351.RAfxw3GWNnFVfM9fhovClKpH1xoAqrs3Q3zBz_3q45euI130_assertion wasGeneratedBy ECO_0000203 NP1238351.RAfxw3GWNnFVfM9fhovClKpH1xoAqrs3Q3zBz_3q45euI130_provenance.